Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Hard Copy Alzheimers and Parkinsons Disease - Global Strategic Business Report Global Industry Analysts, Inc., May 2008, Pages: 530   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   This report analyzes the worldwide markets for Alzheimer’s and Parkinson’s Disease in Millions of US$. The Major product segments Analyzed are Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors, & NMDARA), and Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, & Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine Amplifiers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 87 companies including many key and niche players worldwide such as Boehringer Ingelheim, Bristol-Myers Squibb Co., Eisai Inc., Eli Lilly and Company, Forest Pharmaceuticals, GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Novartis AG, Ortho-McNeil Neurologics, Inc., Pfizer Inc., Roche, Shire Pharmaceuticals Group PLC, and Valeant Pharmaceuticals International. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying Customers who bought this item also bought Pipeline Insight: Parkinsons Disease And Restless Legs Syndrome - Reformulations Set To Drive Near-Term Growth Stakeholder Opinions: Parkinsons Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market Emerging Diagnostic Markers in Alzheimers Disease Eyeglasses - Global Strategic Business Report Alzheimers Disease - Beta Treatments On The Horizon Cardiovascular Disease Diagnostics - Global Strategic Business Report Strategic Analysis of World Emerging Neurological Therapeutics Markets PharmaVitae 2004: Roche Global and US Analysis

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster